

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO. 3001
TO BE ANSWERED ON 19th AUGUST, 2025**

INCREASE IN CASES OF MDR AND XDR-TB

3001 SMT. RAJANI ASHOKRAO PATIL:

Will the **Minister of HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether there has been an increase in cases of multi-drug-resistant (MDR) and Extensively Drug-Resistant Tuberculosis (XDR-TB) in the last two years;
- (b) the number of DR-TB cases reported in 2023 and 2024, State-wise;
- (c) whether there are adequate DR-TB treatment centres across high-burden districts;
- (d) whether India's National Strategic Plan for TB Elimination (2020–2025) is on track; and
- (e) the steps being taken to ensure uninterrupted supply of newer TB drugs like Bedaquiline and Delamanid?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY
WELFARE
(SMT. ANUPRIYA PATEL)**

(a) to (e) The National TB Elimination Programme (NTEP) is implemented across the country under the aegis of the National Health Mission (NHM). With enhanced efforts by the Government to identify all TB cases, the notification of TB cases has increased consistently. Under NTEP, the number of reported cases of multi-drug-resistant (MDR) and Extensively Drug-Resistant Tuberculosis (XDR-TB) in the last two years is as under:

Type of case reported	2023 (Jan – Dec)	2024 (Jan – Dec)
Multi-drug-resistant (MDR) TB	63,815	59,036
Extensively Drug-Resistant Tuberculosis (XDR-TB)	114	146

The State-wise details of drug resistant TB cases reported is placed as **Annexure**.

To ensure access to appropriate treatment, 815 Drug Resistant TB treatment centres have been established covering all districts of the country.

As per the World Health Organisation's Global TB Report, 2024, the incidence rate of TB in India has shown a 17.7% decline from 237 per lakh population in 2015 to 195 per lakh population in 2023, which is more than double the global reduction, while deaths due to TB has reduced by 21.4% from 28 per lakh population in 2015 to 22 per lakh population in 2023.

Under NTEP, adequate availability and uninterrupted supply of anti-TB drugs including Bedaquiline, Pretomanid, Linezolid & Moxifloxacin is ensured. The Government conducts regular assessment to monitor stock levels across states /UTs. Release Orders / Transfers Orders are issued routinely from central level to the State/UTs to replenish the stock position of anti TB drugs. Additionally, States and UTs have been equipped with resources under NHM for local procurement of anti-tuberculosis drugs in limited quantities, to address any emergent needs promptly.

Annexure referred to in reply to parts (a) to (e) of Rajya Sabha Unstarred Question No. 3001 for answer on 19.08.2025.

Annexure

State-wise details of drug-resistant TB cases (including MDR and XDR-TB) reported under NTEP for 2023 & 2024 are as below:

States/UTs	2023 (Jan-Dec)	2024 (Jan-Dec)
Andaman & Nicobar Islands	67	41
Andhra Pradesh	1264	1506
Arunachal Pradesh	157	173
Assam	900	821
Bihar	4633	4442
Chandigarh	132	75
Chhattisgarh	463	384
Dadra and Nagar Haveli and Daman and Diu	28	18
Delhi	3173	2863
Goa	37	41
Gujarat	2806	2278
Haryana	1972	1920
Himachal Pradesh	227	204
Jammu & Kashmir	150	139
Jharkhand	1179	1097
Karnataka	1650	1423
Kerala	323	237
Ladakh	6	0
Lakshadweep	1	0
Madhya Pradesh	3896	3602
Maharashtra	10340	9380
Manipur	62	49
Meghalaya	250	191
Mizoram	154	158
Nagaland	111	104
Odisha	505	444
Puducherry	15	9
Punjab	960	1007
Rajasthan	4535	4273
Sikkim	153	162
Tamil Nadu	1822	1340
Telangana	1547	1412
Tripura	37	38
Uttar Pradesh	17013	16436
Uttarakhand	528	587
West Bengal	2833	2328